Stock Financial Ratios, Dividends, Split History
CSTR / CapStar Financial Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||230.99|
|Enterprise Value ($M)||175.32|
|Book Value ($M)||148.69|
|Book Value / Share||12.75|
|Price / Book||1.55|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Common Shares Outstanding||11,560,593|
|Common Shares Outstanding2||132,561|
|Preferred Stock Shares Outstanding||878,049|
|Weighted Average Number Of Shares Outstanding Basic||11,280,580|
|Weighted Average Number Of Diluted Shares Outstanding||12,803,511|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.01|
|Return on Assets (ROA)||0.00|
|Return on Equity (ROE)||0.01|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1676479|
Stock splits are used by CapStar Financial Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
9h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
Related News Stories
Bank of the Ozarks Inc.’s (OZRK - Free Report) second-quarter 2018 earnings per share of 89 cents came in line with the Zacks Consensus Estimate of 89 cents. The reported figure represents year-over-year growth of 21.9%. Results primarily benefited from an improvement in net interest income. Also, loans and deposit balances improved, which supported results to some extent. However, elevated expenses, lower non-interest income and higher provisions were the undermining factors. (1-0)
Driven by strength in fundamentals and good growth prospects, Community Trust Bancorp, Inc. (CTBI - Free Report) looks like a solid investment option right now. Further, the company has been witnessing upward earnings estimate revisions off late, reflecting that analysts are optimistic about its earnings growth potential. The company’s Zacks Consensus Estimate for the current-year earnings has been revised 1.
Ameris Bancorp (ABCB - Free Report) recently completed the acquisition of Hamilton State Bancshares, Inc., in an effort to expand into the Atlanta markets. Consequently, Hamilton State Bank, the banking subsidiary of Hamilton has been merged with Ameris’ subsidiary, Ameris Bank. Hamilton, with nearly $1.8 billion in assets, conducted its operations through almost 28 banking locations. At the time of the announcement of the deal, Edwin W. (2-0)
An improving operating backdrop, a rising-rate environment and easing of regulations, along with the strengthening of the domestic economy, should keep aiding banking stocks. So, we bring one such stock — Fidelity Southern Corporation (LION - Free Report) — which, based on its strong fundamentals and improving prospects, is a good investment option right now. The company’s Zacks Consensus Estimate for current-year earnings has been revised 3. (19-0)
Given that the banking industry remains well positioned for growth, driven by the Fed rate hikes and the benefits from the gradually stabilizing operating environment, we think that it is a wise idea to add a few stocks from that industry to your portfolio now. Based on its underlying strength and good growth prospects, First BanCorp. (FBP - Free Report) stock seems to be a solid bet now. The company’s Zacks Consensus Estimate for current-year earnings has been revised 32. (27-0)
as of ET